Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension safety study of eptinezumab in Japanese patients with migraine
jRCT2071210060Completed
- Sponsor
- Lundbeck
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of eptinezumab in migraine, sponsored by Lundbeck. Primary endpoint: Number of Participants With Adverse Events (AEs). Started Sep 2021; status: completed.
02
Drugs
eptinezumab
03
Conditions
migraine
Beyond the preview
Go deeper on jRCT2071210060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210060.